Abstract: Disclosed is a compound represented by formula (1) or a salt thereof, formula (1): wherein X is a residue of a compound having activity of binding to at least one member selected from the group consisting of amyloid ? proteins, tau proteins, ?-synuclein, and TDP-43; m is an integer of 0 to 6; n is an integer of 1 to 5; and J is a group selected from the group consisting of wherein R1 and R2 are each independently a hydrogen atom, a fluorine atom, methyl, or trifluoromethyl; R3 is trifluoromethyl or trifluoromethoxy; and p is an integer of 1 to 4, provided that m+n?5 when J is J-1, and m+n?7 when J is J-2 or J-3.

Abstract: Disclosed are a curcumin derivative or a salt thereof, which contains a fluorine atom, represented by formula (I): (wherein R1a and R1b are each independently a hydrogen atom, alkyl, acetyl, or methoxycarbonyl; R2s are each independently a fluorine atom, CHF2—, CF3—, CHF2O—, or CF3O—; R3s are each independently a hydrogen atom or a fluorine atom; A is alkyl, cyano, carboxyl, alkoxycarbonyl, or R4—(CH2)m—; R4 is hydroxy, carboxy, cyano, acetyloxy, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkoxy, or CONR5R6; R5 and R6 are each independently a hydrogen atom or alkyl; and m is an integer from 1 to 5), and a diagnostic imaging agent for diagnosing a disease in which an amyloid ? peptide aggregate accumulates, the diagnostic imaging agent containing a compound having a 1,3-dicarbonyl structure, wherein the compound exists in a keto form and an enol form, and the keto form and the enol form have different affinities, respectively, to the amyloid ? peptide aggregate.

Abstract: Disclosed herein is a method for diagnosing Alzheimer's disease capable of minimizing invasiveness to reduce the risk of infection. The method for diagnosing Alzheimer's disease includes the steps of: pretreating an intranasal specimen; detecting tau protein or amyloid beta peptide (A?) in the pretreated intranasal specimen; comparing a value of the tau protein or the A? obtained in the detection step with a predetermined value; and displaying a comparison result obtained in the comparison step.

Abstract: Disclosed are a curcumin derivative or a salt thereof, which contains a fluorine atom, represented by formula (I): (wherein R1a and R1b are each independently a hydrogen atom, alkyl, acetyl, or methoxycarbonyl; R2s are each independently a fluorine atom, CHF2—, CF3—, CHF2O—, or CF3O—; R3s are each independently a hydrogen atom or a fluorine atom; A is alkyl, cyano, carboxyl, alkoxycarbonyl, or R4—(CH2)m—; R4 is hydroxy, carboxy, cyano, acetyloxy, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkoxy, or CONR5R6; R5 and R6 are each independently a hydrogen atom or alkyl; and m is an integer from 1 to 5), and a diagnostic imaging agent for diagnosing a disease in which an amyloid ? peptide aggregate accumulates, the diagnostic imaging agent containing a compound having a 1,3-dicarbonyl structure, wherein the compound exists in a keto form and an enol form, and the keto form and the enol form have different affinities, respectively, to the amyloid ? peptide aggregate.

Abstract: A gold nanoparticle composition is provided that includes a spherical gold nanoparticle and an organic ligand molecule. The organic ligand molecule bonds to the gold nanoparticle. Thus, the gold nanoparticle composition has at least one absorption peak wavelength (plasmon absorption wavelength) within the region of 600-1000 nm. Consequently, the gold nanoparticle composition self-heats when irradiated with electromagnetic waves having a wavelength of 600-1000 nm.